Every figure on this page comes from documents Ginkgo Bioworks Holdings, Inc. Class A Common Stock filed with the exchange, and each one was checked against the document itself before publication. What could not be verified is not here.
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $20 mn | -48.5% | $-47 mn | +22.5% | -231.7% |
| Mar 2026 | $19 mn | -49.1% | $-83 mn | +9.2% | -424.1% |
| Dec 2025 | $54 mn | +23.1% | $-81 mn | — | -149.7% |
| Sep 2025 | $39 mn | -56.4% | $-81 mn | -43.2% | -207.9% |
| Jun 2025 | $39 mn | -30.4% | $-60 mn | +72.2% | -154.1% |
| Mar 2025 | $38 mn | +0.8% | $-91 mn | — | -237.9% |
Watch it, and each morning it files something you get the checked numbers, the sources, and red-flag alerts when the quiet numbers move — pledges, ratings, resignations. Ask by name any evening and it is read overnight.
Start free — first week on us →Data from documents filed with the exchanges, checked against the documents themselves. This page states facts and is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI and verified against filed documents. Terms, disclosures and grievances